Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 560

1.

Substance P and Inflammatory Pain: Getting It Wrong and Right Simultaneously.

Navratilova E, Porreca F.

Neuron. 2019 Feb 6;101(3):353-355. doi: 10.1016/j.neuron.2019.01.034.

PMID:
30731054
2.

Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).

Guerrero M, Urbano M, Kim EK, Gamo Albero AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie J, Porreca F, Cameron MD, Rosen H, Roberts E.

J Med Chem. 2019 Feb 1. doi: 10.1021/acs.jmedchem.8b01679. [Epub ahead of print]

PMID:
30707578
3.

Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain.

Navratilova E, Ji G, Phelps C, Qu C, Hein M, Yakhnitsa V, Neugebauer V, Porreca F.

Pain. 2018 Dec 3. doi: 10.1097/j.pain.0000000000001458. [Epub ahead of print]

PMID:
30681985
4.

Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache.

Nation KM, Dodick DW, Navratilova E, Porreca F.

Cephalalgia. 2018 Oct 4:333102418804157. doi: 10.1177/0333102418804157. [Epub ahead of print]

PMID:
30286616
5.

Kappa Opioid Receptor Distribution and Function in Primary Afferents.

Snyder LM, Chiang MC, Loeza-Alcocer E, Omori Y, Hachisuka J, Sheahan TD, Gale JR, Adelman PC, Sypek EI, Fulton SA, Friedman RL, Wright MC, Duque MG, Lee YS, Hu Z, Huang H, Cai X, Meerschaert KA, Nagarajan V, Hirai T, Scherrer G, Kaplan DH, Porreca F, Davis BM, Gold MS, Koerber HR, Ross SE.

Neuron. 2018 Sep 19;99(6):1274-1288.e6. doi: 10.1016/j.neuron.2018.08.044.

PMID:
30236284
6.

Positive allosteric modulators of nonbenzodiazepine γ-aminobutyric acidA receptor subtypes for the treatment of chronic pain.

Johnstone TBC, Xie JY, Qu C, Wasiak DJ, Hogenkamp DJ, Porreca F, Gee KW.

Pain. 2019 Jan;160(1):198-209. doi: 10.1097/j.pain.0000000000001392.

PMID:
30204648
7.

The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.

Flores AJ, Bartlett MJ, Root BK, Parent KL, Heien ML, Porreca F, Polt R, Sherman SJ, Falk T.

Neuropharmacology. 2018 Oct;141:260-271. doi: 10.1016/j.neuropharm.2018.09.005. Epub 2018 Sep 7.

PMID:
30201210
8.

Inhibition of experimental visceral pain in rodents by cebranopadol.

Schiene K, Schröder W, Linz K, Frosch S, Tzschentke TM, Christoph T, Xie JY, Porreca F.

Behav Pharmacol. 2018 Aug 29. doi: 10.1097/FBP.0000000000000420. [Epub ahead of print]

PMID:
30161034
9.

Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain.

Gomtsian L, Bannister K, Eyde N, Robles D, Dickenson AH, Porreca F, Navratilova E.

Pain. 2018 Dec;159(12):2512-2521. doi: 10.1097/j.pain.0000000000001355.

PMID:
30086115
10.

Representations of Syrian food by Syrian refugees in the city of São Paulo, Brazil: An ethnographic study.

Scagliusi FB, Porreca FI, Ulian MD, de Morais Sato P, Unsain RF.

Appetite. 2018 Oct 1;129:236-244. doi: 10.1016/j.appet.2018.07.014. Epub 2018 Jul 17.

PMID:
30030138
11.

In Reply.

Garami A, Ibrahim M, Gilbraith K, Khanna R, Pakai E, Miko A, Pinter E, Romanovsky AA, Porreca F, Patwardhan AM.

Anesthesiology. 2018 Aug;129(2):378-379. doi: 10.1097/ALN.0000000000002294. No abstract available.

PMID:
30020181
12.

Selective deficiencies in descending inhibitory modulation in neuropathic rats: implications for enhancing noradrenergic tone.

Patel R, Qu C, Xie JY, Porreca F, Dickenson AH.

Pain. 2018 Sep;159(9):1887-1899. doi: 10.1097/j.pain.0000000000001300.

13.

Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors.

Remesic M, Macedonio G, Mollica A, Porreca F, Hruby V, Lee YS.

Bioorg Med Chem. 2018 Jul 23;26(12):3664-3667. doi: 10.1016/j.bmc.2018.05.045. Epub 2018 May 26.

PMID:
29858157
14.

The opioid crisis and … reconsidering the use of drugs that affect body temperature.

Patwardhan A, Porreca F, Schmidt WK, Romanovsky AA.

Temperature (Austin). 2018 Mar 6;5(1):1-3. doi: 10.1080/23328940.2018.1437312. eCollection 2018. No abstract available.

PMID:
29687038
15.

Chronic pain impairs cognitive flexibility and engages novel learning strategies in rats.

Cowen SL, Phelps CE, Navratilova E, McKinzie DL, Okun A, Husain O, Gleason SD, Witkin JM, Porreca F.

Pain. 2018 Jul;159(7):1403-1412. doi: 10.1097/j.pain.0000000000001226.

PMID:
29578947
16.

Lateralized kappa opioid receptor signaling from the amygdala central nucleus promotes stress-induced functional pain.

Nation KM, De Felice M, Hernandez PI, Dodick DW, Neugebauer V, Navratilova E, Porreca F.

Pain. 2018 May;159(5):919-928. doi: 10.1097/j.pain.0000000000001167.

PMID:
29369967
17.

Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer.

Watanabe M, Narita M, Hamada Y, Yamashita A, Tamura H, Ikegami D, Kondo T, Shinzato T, Shimizu T, Fukuchi Y, Muto A, Okano H, Yamanaka A, Tawfik VL, Kuzumaki N, Navratilova E, Porreca F, Narita M.

Mol Pain. 2018 Jan-Dec;14:1744806918756406. doi: 10.1177/1744806918756406. Epub 2018 Jan 22.

18.

Extracellular N-acetylaspartylglutamate released in the nucleus accumbens modulates the pain sensation: Analysis using a microdialysis/mass spectrometry integrated system.

Watanabe M, Sugiura Y, Sugiyama E, Narita M, Navratilova E, Kondo T, Uchiyama N, Yamanaka A, Kuzumaki N, Porreca F, Narita M.

Mol Pain. 2018 Jan-Dec;14:1744806918754934. doi: 10.1177/1744806918754934. Epub 2018 Jan 8.

19.

Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain.

Remeniuk B, King T, Sukhtankar D, Nippert A, Li N, Li F, Cheng K, Rice KC, Porreca F.

Pain. 2018 Apr;159(4):684-698. doi: 10.1097/j.pain.0000000000001139.

PMID:
29300279
20.

Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia.

Godfrey L, Iannitelli A, Garrett NL, Moger J, Imbert I, King T, Porreca F, Soundararajan R, Lalatsa A, Schätzlein AG, Uchegbu IF.

J Control Release. 2018 Jan 28;270:135-144. doi: 10.1016/j.jconrel.2017.11.041. Epub 2017 Nov 27.

21.

Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain.

Bannister K, Qu C, Navratilova E, Oyarzo J, Xie JY, King T, Dickenson AH, Porreca F.

Pain. 2017 Dec;158(12):2386-2395. doi: 10.1097/j.pain.0000000000001040.

22.

Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.

Vardanyan RS, Cain JP, Haghighi SM, Kumirov VK, McIntosh MI, Sandweiss AJ, Porreca F, Hruby VJ.

J Heterocycl Chem. 2017 Mar;54(2):1228-1235. doi: 10.1002/jhet.2696. Epub 2016 Jun 1.

23.

CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.

Moutal A, Yang X, Li W, Gilbraith KB, Luo S, Cai S, François-Moutal L, Chew LA, Yeon SK, Bellampalli SS, Qu C, Xie JY, Ibrahim MM, Khanna M, Park KD, Porreca F, Khanna R.

Pain. 2017 Dec;158(12):2301-2319. doi: 10.1097/j.pain.0000000000001002.

24.

Transient Receptor Potential Vanilloid 1 Antagonists Prevent Anesthesia-induced Hypothermia and Decrease Postincisional Opioid Dose Requirements in Rodents.

Garami A, Ibrahim M, Gilbraith K, Khanna R, Pakai E, Miko A, Pinter E, Romanovsky AA, Porreca F, Patwardhan AM.

Anesthesiology. 2017 Nov;127(5):813-823. doi: 10.1097/ALN.0000000000001812.

PMID:
28806222
25.

Mechanisms of craniofacial pain.

Chichorro JG, Porreca F, Sessle B.

Cephalalgia. 2017 Jun;37(7):613-626. doi: 10.1177/0333102417704187. Epub 2017 Apr 25. Review.

PMID:
28440673
26.

Mediation of Movement-Induced Breakthrough Cancer Pain by IB4-Binding Nociceptors in Rats.

Havelin J, Imbert I, Sukhtankar D, Remeniuk B, Pelletier I, Gentry J, Okun A, Tiutan T, Porreca F, King TE.

J Neurosci. 2017 May 17;37(20):5111-5122. doi: 10.1523/JNEUROSCI.1212-16.2017. Epub 2017 Apr 24.

27.

Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.

Xie JY, De Felice M, Kopruszinski CM, Eyde N, LaVigne J, Remeniuk B, Hernandez P, Yue X, Goshima N, Ossipov M, King T, Streicher JM, Navratilova E, Dodick D, Rosen H, Roberts E, Porreca F.

Cephalalgia. 2017 Jul;37(8):780-794. doi: 10.1177/0333102417702120. Epub 2017 Apr 4.

28.

Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics.

Remesic M, Hruby VJ, Porreca F, Lee YS.

ACS Chem Neurosci. 2017 Jun 21;8(6):1147-1158. doi: 10.1021/acschemneuro.7b00090. Epub 2017 Apr 7. Review.

29.

Reward, motivation, and emotion of pain and its relief.

Porreca F, Navratilova E.

Pain. 2017 Apr;158 Suppl 1:S43-S49. doi: 10.1097/j.pain.0000000000000798. Review. No abstract available.

30.

Long-lasting antinociceptive effects of green light in acute and chronic pain in rats.

Ibrahim MM, Patwardhan A, Gilbraith KB, Moutal A, Yang X, Chew LA, Largent-Milnes T, Malan TP, Vanderah TW, Porreca F, Khanna R.

Pain. 2017 Feb;158(2):347-360. doi: 10.1097/j.pain.0000000000000767.

31.

Efficacy of (S)-Lacosamide in preclinical models of cephalic pain.

Moutal A, Eyde N, Telemi E, Park KD, Xie JY, Dodick DW, Porreca F, Khanna R.

Pain Rep. 2016 Jun;1(1). pii: e565.

32.

Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine.

Rice FL, Xie JY, Albrecht PJ, Acker E, Bourgeois J, Navratilova E, Dodick DW, Porreca F.

Cephalalgia. 2017 Dec;37(14):1350-1372. doi: 10.1177/0333102416677051. Epub 2016 Nov 16.

PMID:
27852962
33.

Structure-Activity Relationships of [des-Arg7]Dynorphin A Analogues at the κ Opioid Receptor.

Ramos-Colon CN, Lee YS, Remesic M, Hall SM, LaVigne J, Davis P, Sandweiss AJ, McIntosh MI, Hanson J, Largent-Milnes TM, Vanderah TW, Streicher J, Porreca F, Hruby VJ.

J Med Chem. 2016 Nov 23;59(22):10291-10298. Epub 2016 Nov 8.

34.

Cyclic non-opioid dynorphin A analogues for the bradykinin receptors.

Lee YS, Remesic M, Ramos-Colon C, Hall SM, Kuzmin A, Rankin D, Porreca F, Lai J, Hruby VJ.

Bioorg Med Chem Lett. 2016 Nov 15;26(22):5513-5516. doi: 10.1016/j.bmcl.2016.10.010. Epub 2016 Oct 6.

35.

Discovery of Stable Non-opioid Dynorphin A Analogues Interacting at the Bradykinin Receptors for the Treatment of Neuropathic Pain.

Hall SM, LeBaron L, Ramos-Colon C, Qu C, Xie JY, Porreca F, Lai J, Lee YS, Hruby VJ.

ACS Chem Neurosci. 2016 Dec 21;7(12):1746-1752. doi: 10.1021/acschemneuro.6b00258. Epub 2016 Sep 27.

36.

Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain.

Okun A, McKinzie DL, Witkin JM, Remeniuk B, Husein O, Gleason SD, Oyarzo J, Navratilova E, McElroy B, Cowen S, Kennedy JD, Porreca F.

Pain. 2016 Dec;157(12):2731-2738.

37.

Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential.

Xie JY, Chew LA, Yang X, Wang Y, Qu C, Wang Y, Federici LM, Fitz SD, Ripsch MS, Due MR, Moutal A, Khanna M, White FA, Vanderah TW, Johnson PL, Porreca F, Khanna R.

Pain. 2016 Sep;157(9):2124-40. doi: 10.1097/j.pain.0000000000000628.

38.

Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents.

Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J, Bigal M, Chichorro JG, Dodick D, Porreca F.

Cephalalgia. 2017 May;37(6):560-570. doi: 10.1177/0333102416650702. Epub 2016 May 19.

PMID:
27206958
39.

Various modifications of the amphipathic dynorphin A pharmacophore for rat brain bradykinin receptors.

Lee YS, Kupp R, Remesic MV, Ramos-Colon C, Hall SM, Chan C, Rankin D, Lai J, Porreca F, Hruby VJ.

Chem Biol Drug Des. 2016 Oct;88(4):615-9. doi: 10.1111/cbdd.12789. Epub 2016 Jun 6.

40.

Activation of dura-sensitive trigeminal neurons and increased c-Fos protein induced by morphine withdrawal in the rostral ventromedial medulla.

Hitomi S, Kross K, Kurose M, Porreca F, Meng ID.

Cephalalgia. 2017 Apr;37(5):407-417. doi: 10.1177/0333102416648655. Epub 2016 May 6.

PMID:
27155000
41.

(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.

Moutal A, Chew LA, Yang X, Wang Y, Yeon SK, Telemi E, Meroueh S, Park KD, Shrinivasan R, Gilbraith KB, Qu C, Xie JY, Patwardhan A, Vanderah TW, Khanna M, Porreca F, Khanna R.

Pain. 2016 Jul;157(7):1448-63. doi: 10.1097/j.pain.0000000000000555.

42.

Positive emotions and brain reward circuits in chronic pain.

Navratilova E, Morimura K, Xie JY, Atcherley CW, Ossipov MH, Porreca F.

J Comp Neurol. 2016 Jun 1;524(8):1646-52. doi: 10.1002/cne.23968. Epub 2016 Feb 3. Review.

43.

Central Sensitization and Neuropathic Features of Ongoing Pain in a Rat Model of Advanced Osteoarthritis.

Havelin J, Imbert I, Cormier J, Allen J, Porreca F, King T.

J Pain. 2016 Mar;17(3):374-82. doi: 10.1016/j.jpain.2015.12.001. Epub 2015 Dec 13.

44.

Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE considerations.

Andrews NA, Latrémolière A, Basbaum AI, Mogil JS, Porreca F, Rice AS, Woolf CJ, Currie GL, Dworkin RH, Eisenach JC, Evans S, Gewandter JS, Gover TD, Handwerker H, Huang W, Iyengar S, Jensen MP, Kennedy JD, Lee N, Levine J, Lidster K, Machin I, McDermott MP, McMahon SB, Price TJ, Ross SE, Scherrer G, Seal RP, Sena ES, Silva E, Stone L, Svensson CI, Turk DC, Whiteside G.

Pain. 2016 Apr;157(4):901-9. doi: 10.1097/j.pain.0000000000000458. Review.

45.

Brain Circuits Encoding Reward from Pain Relief.

Navratilova E, Atcherley CW, Porreca F.

Trends Neurosci. 2015 Nov;38(11):741-750. doi: 10.1016/j.tins.2015.09.003. Review.

46.

Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas.

Becerra L, Bishop J, Barmettler G, Xie Y, Navratilova E, Porreca F, Borsook D.

J Neurophysiol. 2016 Jan 1;115(1):208-17. doi: 10.1152/jn.00632.2015. Epub 2015 Oct 21.

47.

Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.

Giri AK, Apostol CR, Wang Y, Forte BL, Largent-Milnes TM, Davis P, Rankin D, Molnar G, Olson KM, Porreca F, Vanderah TW, Hruby VJ.

J Med Chem. 2015 Nov 12;58(21):8573-83. doi: 10.1021/acs.jmedchem.5b01170. Epub 2015 Oct 30.

48.

Alterations in the rostral ventromedial medulla after the selective ablation of μ-opioid receptor expressing neurons.

Harasawa I, Johansen JP, Fields HL, Porreca F, Meng ID.

Pain. 2016 Jan;157(1):166-73. doi: 10.1097/j.pain.0000000000000344.

49.

Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.

Deekonda S, Wugalter L, Rankin D, Largent-Milnes TM, Davis P, Wang Y, Bassirirad NM, Lai J, Kulkarni V, Vanderah TW, Porreca F, Hruby VJ.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4683-8. doi: 10.1016/j.bmcl.2015.07.064. Epub 2015 Jul 29.

50.

Design, synthesis and biological evaluation of multifunctional ligands targeting opioid and bradykinin 2 receptors.

Deekonda S, Rankin D, Davis P, Lai J, Porreca F, Hruby VJ.

Bioorg Med Chem Lett. 2015 Oct 1;25(19):4148-52. doi: 10.1016/j.bmcl.2015.08.014. Epub 2015 Aug 14.

Supplemental Content

Loading ...
Support Center